Key facts
- This page summarizes Wendy E. Blosser's Form 3 filing for Accustem Sciences Inc. (ACUT).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 May 2022, 10:37.
Wendy E. Blosser - 04 Mar 2022 Form 3 Insider Report for Accustem Sciences Inc. (ACUT)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ACUT
- Reported as of
- 04 Mar 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Wendy Blosser
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Wendy E. Blosser filed Form 3 for Accustem Sciences Inc. (ACUT) on 27 May 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACUT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,000
- Date
- 04 Mar 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACUT
holding
Derivative
Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 490,000
- Exercise price
- $2.13
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
49,000 of the options vest on January 25, 2023, 2024 and 2025 and 98,000 vest on January 25, 2026. 122,500 options vest upon the closing of a single equity raise netting not less than $30m for the Company; and 122,500 options vest upon the opening of a commercial CLIA lab in the U.S. no later than the fourth quarter 2023.